



European Monitoring Centre  
for Drugs and Drug Addiction

# HBV & HCV Elimination Barometer for PWID in Europe


Thomas Seyler, Public Health Unit - EMCDDA

DRID 2018




# Background

- Elimination of HBV and HCV as a public health threat by 2030



# Background

- WHO Monitoring and Evaluation for viral hepatitis B&C



Source: WHO

# Background

- **ECDC EU hepatitis B&C monitoring platform**
  - Epidemic context (4)
  - Prevention (15)
  - Cascade of care (14)
  - Impact (3)
  
- **European coverage targets (WHO Europe)**

<b>Indicator</b>	<b>2020 Target</b>
HEPB3 coverage	<b>95%</b>
HBV vaccine birth dose coverage, or other approaches	<b>90%</b>
Donations screened with quality assured methods	<b>100%</b>
Proportion of injections with safety engineered devices	<b>50%</b>
Injection kits distributed/year/PWID	<b>200</b>
% HBV/HCV-infected diagnosed	<b>50%</b>
% HBV diagnosed on treatment / % HCV diagnosed started treatment	<b>75%</b>




# Objective


- **Provide a complementary PWID-specific monitoring framework** – what should be done?
  - Simple, acceptable, documented
  - Provides a framework for discussion with member states (MS)
  
- **Identify data gaps** – what do we still need to know?
  - Missing/old data, low level of evidence
  - Encourages MS to report
  
- **Assess how far we are from targets** - where do we need to allocate resources?



# 16 Core indicators among PWID



# Additional indicators among PWID



Source: adapted from WHO


# Methods: data sources

- **Reitox network**
  - 30 National experts at national focal points
  - DRID, PDU, TDI networks
  
- **Case definitions**
  - EMCDDA indicators protocols
  
- **Data collection and validation**
  - FONTE data collection platform (quantitative)
  - Workbooks from NFP (qualitative)
  - Projects
  
- **Targets**
  - WHO targets
  - Complementary targets




# Context and needs

- Prevalence of injecting drug use in the EU and Norway, 2011-16



# Context and needs


- Prevalence estimates of HCV antibody and HBV surface antigen among people who inject drugs in Europe, 2014-15



Source: European Drug Report 2017

# Inputs


- Countries with viral hepatitis policy inclusive of PWID, EU&Norway, 2018



Source: EMCDDA

# Prevention

- Yearly number of syringes distributed per person who injects drugs in Europe and Norway, 2016 estimates




NB: Data displayed as point estimates and uncertainty intervals.



# Prevention


- Percentage of estimated high-risk opioid users receiving opioid substitution treatment, 2016 estimates



NB: Data displayed as point estimates and uncertainty intervals.

# Testing

- Percentage of PWID (excluding known HCV-infected) reporting a HCV test in the last 12 months, European studies, 2013-16




Source: FONTE

# Cascade of care

- No routine exhaustive data collection
- Some studies

Continuum of HCV Care in an Outreach Program for Intravenous Drug Users in Luxembourg, 2015-17


*A. Fischer, N. Da Silva, H. Goedertz, R. Karier, M. Menster, G. Ambroset, V. Etienne, L. Guillorit, E. Andlauer, T. Staub, V. Arendt and C. Devaux*



# Impact

- Prevalence in young and recent injectors

Prevalence of hepatitis C virus infection among people who inject drugs, by age, 2015 to 2016



- Presentation on ‘*Model Projection to estimate the impact of HCV prevention and treatment interventions in Europe*’, Hannah Fraser, University of Bristol



# The Elimination Barometer

Country/indicator	TEXT AND NEEDS								INPUTS	OUTPUTS AND O										
	Prevalence of HBV (HBsAg+)			PWID size		Pattern of drug use				Prevention					Testing					
	Sample size	National prevalence	Sub-national prevalence	Prevalence of PWID per 1000 (with uncertainty intervals)	Number of PWID (with uncertainty intervals)	Main substance(s) injected	% sharing used needles/syringes in the last 4 weeks	% sharing used paraphernalia in the last 4 weeks		Hepatitis policy inclusive of PWID in place	IEC coverage (NSP clients/PWID) %	Syringes per estimated PWID per year	% of HROU receiving opioid substitution treatment	Targeted HBV vaccination for high-risk groups in place (Prison, Drug services,...)	Starting year of HBV universal vaccination	HBV vaccine coverage among PWID (%)	Community based HCV testing available	HCV testing available in drug services	HCV testing available in prison	% of ever PWID entering drug treatment tested for HCV in the last 12 months
Belgium	391		1.9-5.6	3.28 (2.32 - 4.61)	23828 (16841 - 33517)	Heroin	20.6 (2006)	16.4 (2010)	yes		47		no (2012)	1999		yes	yes	yes		
Bulgaria	691		1.81-8.6				47	45.6	no				no (2012)	1993		yes	yes			45
Czech Republic				6.14 (6 - 6.27)	42800 (41800 - 43700)	Heroin	20.52	78.9 (2003)	no	75	151	40	no (2012)	2000		yes	yes	no (2012)		58,51
Germany	2077		0.3-2.3				10,62	32,95	yes			48		1995			yes			28.77-75.36
Estonia	326		4				10,28	21,45	no				yes (prison)	2003			yes	yes		34.7 (2010)
Spain	2002	10,5		0.36 (0.22 - 0.49)	11048 (6818 - 15278)	Heroin			yes		130	>50	yes	1996		yes	yes	yes	43	
France	908		0,81	2.68 (2.11 - 3.81)	108607 (85688 - 154750)	Cocaine	14,48	24,39	yes	39	113	80	(drug centre)	2009		yes	yes	yes	8	65,84
Latvia	940	2,4		9.22 (7.34 - 11.68)	12573 (10003 - 15914)	Amphet	0,9	17,6	yes	18	57	10	no (2012)	1993		yes	yes	no (2012)	31	94,9
Lithuania	200		10,5	4.63 (4.37 - 4.89)	8868 (8371 - 9364)	Heroin	14	7,5	no	40	27	16	yes (prison)	1998		no (2012)		no (2012)		100 (2006)
Luxembourg				3,77	1467	Heroin	27.01 (2007)		yes		289	57	yes	1997		yes	yes	yes	on last 12	84.15 (2007)
Malta									no			60	yes	1997		yes	yes	yes	11	
Slovakia	51		0				0 (2010)	0 (2010)	no				no (2012)	1999		yes	yes	yes		86,49
United Kingdom	3485		0.4 - 0.6	3 (2.87 - 3.22)	122894 (117370 - 131869)	Heroin	16,85	13,63	yes			56	yes	2017		yes	yes	yes	6	49-97.3
Norway	227		0,0	2.5 (2.31 - 3.14)	8888 (7581 - 10720)	Heroin	12 (2012)	34 (2012)	yes		238	45	yes	2017	47.05	yes	yes	yes		26



# Conclusions and recommendations

- **Data gaps on PWID**
  - PWID population size estimates: capacity building at EMCDDA (PDU)
    - 3 new estimates this year
  - HBV and HCV prevalence estimates studies among PWID
    - Data session on assessing the level of evidence
  - Behavioural data: can be reported independently of prevalence
    - Data session on behavioural data
  - Testing: using TDI data?
  - Cascade of care among PWID : from studies?
  
- **Feedback on list of indicators and draft country-specific barometer**
  - Agreement on key indicators
  - Suggest additional indicators
  - Some qualitative indicator might require updates
  - Proposal: to have the barometer on the EMCDDA website by 2019



# Acknowledgments

- National experts: DRID network
- WHO: Antons Mozalevskis, Yvan Hutin
- ECDC: Erika Duffell
- EMCDDA : Dagmar Hedrich, Eleni Kalamara, Isabelle Giraudon, Klaudia Palczak

